| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We made the study of laeverin which was released from EVT and combined with immune cells. As recombinant laeverin altered the morphology of villous cells, we suspected laeverin was associated with the immunological escape mechanism.
And we also evaluated the possibility of laeverin could be a prospective marker for the PIH. As we detected the declining trend for the laeverin serum level of PIH patients, we suspected laeverin would be the predictive marker.
|
